Positive and negative elements modulate the promoter of the human liver-specific α2-HS-glycoprotein gene

被引:18
|
作者
Banine, F
Gangneux, C
Mercier, L
Le Cam, A
Salier, LP
机构
[1] Fac Med Pharm, INSERM, U519, F-76183 Rouen, France
[2] Inst Federatif Rech Multidisciplinaires Peptides, Rouen, France
[3] Fac Med Pharm, Lab Histol Embryol, Angers, France
[4] INSERM, U376, Montpellier, France
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 2000年 / 267卷 / 04期
关键词
alpha; 2-HS-glycoprotein; hepatic transcription; NF-1; promoter; silencer;
D O I
10.1046/j.1432-1327.2000.01119.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The human alpha 2-HS-glycoprotein (AHSG) and the 63-kDa rat phosphoprotein (pp63) are homologous plasma proteins that belong to the fetuin family. AHSG and pp63 are involved in important functions such as inhibition of insulin receptor tyrosine kinase activity, inhibition of protease activities, and regulation of calcium metabolism and osteogenesis. Studies of the AHSG proximal promoter performed in vitro, in rat and human cells indicate that several NF-1 and C/EBP binding sites exert a positive effect on its transcriptional activity. However, until now, no distal elements have been examined in this gene, in either species. We report that the human AHSG gene promoter acts in a liver-specific manner and is further controlled by three distal, 5'-flanking elements. The negative elements III and I are, respectively, located 5' and 3' of the positive element II. All three elements require the natural context of the human AHSG gene to fully exert their negative or positive effect. Element I harbours a single binding site for NF-1. This nuclear factor thus appears to be able to up- or downregulate the AHSG gene depending on the site it binds to. Elements I, II and possibly III are absent in the rodent Ahsg gene encoding pp63.
引用
收藏
页码:1214 / 1222
页数:9
相关论文
共 50 条
  • [1] LIVER-DIRECTED GENE-THERAPY - EVALUATION OF LIVER-SPECIFIC PROMOTER ELEMENTS
    HAFENRICHTER, DG
    PONDER, KP
    RETTINGER, SD
    KENNEDY, SC
    WU, XY
    SAYLORS, RS
    FLYE, MW
    JOURNAL OF SURGICAL RESEARCH, 1994, 56 (06) : 510 - 517
  • [2] The liver-specific promoter of the human insulin-like growth factor-II gene contains two negative regulatory elements
    Rodenburg, RJT
    Krijger, JJT
    Holthuizen, PE
    Sussenbach, JS
    FEBS LETTERS, 1996, 394 (01) : 25 - 30
  • [3] Isolation of a liver-specific promoter for human growth hormone receptor gene
    Zou, LL
    Burmeister, LA
    Sperling, MA
    ENDOCRINOLOGY, 1997, 138 (04) : 1771 - 1774
  • [4] POSITIVE AND NEGATIVE REGULATORY ELEMENTS IN THE HUMAN ERBB-2 GENE PROMOTER
    CHEN, YY
    GILL, GN
    ONCOGENE, 1994, 9 (08) : 2269 - 2276
  • [5] The human growth hormone receptor gene - characterisation of the liver-specific promoter
    Rivers, CA
    Norman, MR
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2000, 160 (1-2) : 51 - 59
  • [6] BINDING OF A LIVER-SPECIFIC FACTOR TO THE HUMAN ALBUMIN GENE PROMOTER AND ENHANCER
    FRAIN, M
    HARDON, E
    CILIBERTO, G
    SALATREPAT, JM
    MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (03) : 991 - 999
  • [7] LIVER-SPECIFIC ELEMENTS IN THE PROMOTER REGION OF THE CHOLESTEROL 7-ALPHA HYDROXYLASE GENE
    COOPER, A
    CHEN, J
    CAO, Y
    TANAGUCHI, T
    LEVYWILSON, B
    CIRCULATION, 1995, 92 (08) : 1387 - 1387
  • [8] Glycoproteogenomics: A Frequent Gene Polymorphism Affects the Glycosylation Pattern of the Human Serum Fetuin/α-2-HS-Glycoprotein
    Lin, Yu-Hsien
    Zhu, Jing
    Meijer, Sander
    Franc, Vojtech
    Heck, Albert J. R.
    MOLECULAR & CELLULAR PROTEOMICS, 2019, 18 (08) : 1479 - 1490
  • [9] Liver-specific properties of the human factor VII promoter
    Greenberg, DL
    Miao, CH
    Chung, DW
    Davie, EW
    BLOOD, 1995, 86 (10) : 1104 - 1104
  • [10] Liver-specific expression of an exogenous gene controlled by human apolipoprotein A-I promoter
    Hu, Yurong
    Ren, Xueling
    Wang, Hui
    Ma, Yue
    Wang, Lei
    Shen, Yingying
    Oka, Kazuhiro
    Zhang, Zhenzhong
    Zhang, Yun
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 398 (1-2) : 161 - 164